Alimera Sciences (ALIM) News
Market Cap: $301.29M
Avg Volume: 866.83K
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
ANI Pharmaceuticals, Inc. Completes Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today announced the completion of its previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”).
globenewswire.com
Read More
ANI Pharmaceuticals Initiates Closing of Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (“ANI” or the “Company”) announced today that the Company has initiated closing logistics for the previously announced acquisition of Alimera Sciences, Inc. (Nasdaq: ALIM).
globenewswire.com
Read More
Alimera Sciences (ALIM) Soars 6.6%: Is Further Upside Left in the Stock?
Alimera Sciences (ALIM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
zacks.com
Read More
ANI Pharmaceuticals Provides Update on Closing of Acquisition of Alimera Sciences
PRINCETON, N.J., Sept. 10, 2024 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (“ANI” or “the Company”) (Nasdaq: ANIP) today provided an update on the status of the completion of its previously announced acquisition of Alimera Sciences, Inc. (“Alimera”) (Nasdaq: ALIM).
globenewswire.com
Read More
Alimera Sciences (ALIM) Reports Q2 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.03. This compares to loss of $0.44 per share a year ago.
zacks.com
Read More
Alimera Sciences Reports Second Quarter 2024 Results
ATLANTA, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2024. Alimera will not host a conference call today due to the recently announced agreement to be acquired by ANI Pharmaceuticals, Inc. (“ANI”).
globenewswire.com
Read More
ALIM ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc.
New York, July 27, 2024 (GLOBE NEWSWIRE) -- NEW YORK, July 27, 2024 / GlobeNewswire/-- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
globenewswire.com
Read More
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. - ALIM
NEW YORK , July 26, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc. (Nasdaq: ALIM), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
prnewswire.com
Read More
SHAREHOLDER ALERT: The M&A Class Action Firm Investigates Merger of The Alimera Sciences, Inc. – ALIM
NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Monteverde & Associates PC (the “M&A Class Action Firm”), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Alimera Sciences, Inc . ( N asdaq: ALIM ), relating to its proposed merger with ANI Pharmaceuticals, Inc. Under the terms of the agreement, Alimera Sciences shareholders will receive $5.50 per share, and one contingent value right which shall represent the right to receive up to $0.50 per share contingent on reaching certain net revenue targets in 2026 and 2027.
globenewswire.com
Read More
SHAREHOLDER ALERT: Weiss Law Investigates Alimera Sciences, Inc.
NEW YORK, NY / ACCESSWIRE / June 26, 2024 / Weiss Law is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alimera Sciences, Inc. ("Alimera" or the "Company") (NASDAQ:ALIM), in connection with its acquisition by ANI Pharmaceuticals, Inc. (NASDAQ: ANIP). Under the merger agreement, the Company's shareholders will receive $5.50per share in cash at closing and one non-tradable contingent value right ("CVR") to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027.
accesswire.com
Read More
Alimera (ALIM) Rises on Merger Deal With ANI Pharmaceuticals
Alimera (ALIM) is set to be acquired by ANI Pharmaceuticals for approximately $381 million in upfront consideration. The transaction is expected to close in the third quarter of 2024.
zacks.com
Read More
Dow Jumps 300 Points; Alimera Sciences Shares Spike Higher
U.S. stocks traded mixed midway through trading, with the Dow Jones index gaining more than 300 points on Monday.
benzinga.com
Read More
Shareholder Alert: Ademi LLP investigates whether Alimera Sciences, Inc. has obtained a Fair Price for its Public Shareholders
MILWAUKEE , June 24, 2024 /PRNewswire/ -- Ademi LLP is investigating Alimera (Nasdaq: ALIM) for possible breaches of fiduciary duty and other violations of law in its transaction with ANI Pharmaceuticals. Click here to learn how to join the https://www.ademilaw.com/case/alimera-sciences-inc or call Guri Ademi toll-free at 866-264-3995.
prnewswire.com
Read More
Why Is Alimera Sciences (ALIM) Stock Up 77% Today?
Alimera Sciences (NASDAQ: ALIM ) stock is rocketing higher on Monday after the pharmaceutical company announced an acquisition deal with ANI Pharmaceuticals (NASDAQ: ANIP ). This agreement will have ANI Pharmaceuticals paying $5.50 per share for ALIM stock.
investorplace.com
Read More
ALIM Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Alimera Sciences to ANI Pharmaceuticals
MONSEY, N.Y., June 24, 2024 (GLOBE NEWSWIRE) -- The law firm of Wohl & Fruchter LLP is investigating the fairness of the proposed sale of Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”) to ANI Pharmaceuticals (“ANI”) for $5.50 per share in cash, plus a contingent value right (CVR) of $0.50 per share upon the achievement of certain net revenue milestones.
globenewswire.com
Read More
Alimera Sciences stock rallies 75% on ANI Pharmaceuticals deal
Alimera Sciences Inc (NASDAQ: ALIM) rallied a whopping 75% in premarket today after ANI Pharmaceuticals Inc (NASDAQ: ANIP) said it will buy the Alpharetta, Georgia based company for about $381 million. ANI shares are roughly flat at writing.
invezz.com
Read More
ALIM Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Alimera Sciences, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Alimera Sciences, Inc. (NASDAQ: ALIM) to ANI Pharmaceuticals, Inc. for $5.50 per share in cash at closing and one non-tradable contingent value right representing the right to receive up to $0.50 per share upon the achievement of certain net revenue targets in 2026 and 2027 is fair to Alimera shareholders. Halper Sadeh encourages Alimera shareholders to click here to learn more about t.
businesswire.com
Read More
Alimera Sciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, June 04, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that, pursuant to Nasdaq Listing Rule 5635(c)(4) and in connection with the appointments of five non-executive employees, the Compensation Committee of the Board of Directors of the Company (the “Compensation Committee”) approved, on May 22, 2024 (the “Grant Date”), inducement awards consisting of stock options under the Alimera Sciences, Inc. 2024 Equity Inducement Plan to persons who were not previously employees or who rejoined the Company following a bona fide period of non-employment, as an inducement material to each such new or re-hired employee's employment (collectively, the “Inducement Awards”).
globenewswire.com
Read More
Alimera Sciences, Inc. (ALIM) Q1 2024 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q1 2024 Earnings Conference Call May 14, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President and Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President U.S. Operations Philip Ashman - President, International Operations Conference Call Participants Chase Knickerbocker - Craig-Hallum Yi Chen - H.C. Wainwright & Company Naz Rahman - Maxim Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by.
seekingalpha.com
Read More
Alimera Sciences (ALIM) Reports Q1 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of $0.71 per share a year ago.
zacks.com
Read More
Alimera Sciences Reports First Quarter 2024 Results
ATLANTA, May 14, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2024. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
globenewswire.com
Read More
Alimera Announces First Patient Randomized in Radiation Retinopathy Trial Being Conducted by the DRCR Retina Network
Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy Protocol AL is studying ILUVIEN or faricimab (6.0 mg) injections versus observation for the prevention of visual acuity loss due to radiation retinopathy
globenewswire.com
Read More
New Strong Sell Stocks for March 13th
ASLE, ALIM and CADE have been added to the Zacks Rank #5 (Strong Sell) List on March 13, 2024.
zacks.com
Read More
Alimera Sciences, Inc. (ALIM) Q4 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q4 2023 Earnings Conference Call March 7, 2024 9:00 AM ET Company Participants Scott Gordon - CORE Investor Relations Rick Eiswirth - President & Chief Executive Officer Elliot Maltz - Chief Financial Officer Todd Wood - President, U.S. Operations Conference Call Participants Alex Nowak - Craig-Hallum Capital James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Fourth Quarter and Fiscal Year 2023 Financial Results and Corporate Update Conference Call.
seekingalpha.com
Read More
Alimera Sciences (ALIM) Reports Q4 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.54 per share a year ago.
zacks.com
Read More
Alimera Sciences Reports Fourth Quarter and Full Year 2023 Results
Q4 Net Revenues up 88% to $26.3 million vs. Q4 2022 2023 Net Revenues up 49% to $80.8 million vs. 2022 Increases 2024 Revenue Guidance
globenewswire.com
Read More
The UK National Institute for Health and Care Excellence (NICE) Issues Final Draft Guidance to Provide Patients with a Natural Lens (Phakic Eye) Being Treated for Chronic Diabetic Macular Edema Access to ILUVIEN®
NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME) NICE Final Draft Guidance recommends providing National Health System (NHS) patients with a phakic lens access to the only sustained-release treatment lasting up to 36 months for chronic diabetic macular edema (DME)
globenewswire.com
Read More
Alimera Sciences Names Elliot Maltz as Chief Financial Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced that Elliot Maltz, C.P.A., has been named Chief Financial Officer effective immediately.
globenewswire.com
Read More
Alimera Sciences Appoints Todd Wood as President of U.S. Operations and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ATLANTA, Dec. 12, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera” or the “Company”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health, and maintaining better vision longer, today announced the appointment of Todd Wood as President U.S. effective immediately.
globenewswire.com
Read More
Alimera Appoints Maggie A. Pax to Its Board of Directors
ATLANTA, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces the addition of Maggie A. Pax to its Board of Directors. Ms. Pax presently serves on the board of several life sciences companies.
globenewswire.com
Read More
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.41. This compares to loss of $0.75 per share a year ago.
zacks.com
Read More
Alimera Sciences Reports Third Quarter 2023 Results
ATLANTA, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the third quarter of 2023. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
globenewswire.com
Read More
Alimera Announces Multiple Presentations Highlighting ILUVIEN® and YUTIQ® Data at Retina Society Annual Congress
ATLANTA, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that clinical data for ILUVIEN® (fluocinolone acetonide intravitreal implant) 0.19 mg and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg will be featured in five presentations during the Retina Society's 56th Annual Scientific Meeting being held in New York City from October 11-14, 2023.
globenewswire.com
Read More
Alimera Sciences Appoints Jason Werner as Chief Operating Officer
ATLANTA, Oct. 03, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced the appointment of Jason Werner, Chief Operating Officer (“COO”), effective October 2, 2023. In conjunction with this appointment, Dr. Philip Ashman, previously Alimera's Chief Operating Officer and Senior Vice President, Commercial Operations Europe, was appointed President of International Operations.
globenewswire.com
Read More
Alimera Sciences, Inc. (ALIM) Q2 2023 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2023 Earnings Conference Call August 10, 2023 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President, CEO & Director Russell Skibsted - SVP & CFO Conference Call Participants Alexander Nowak - Craig-Hallum James Molloy - Alliance Global Partners Yi Chen - H.C. Wainwright & Co. Operator Ladies and gentlemen, thank you for standing by.
seekingalpha.com
Read More
Alimera Sciences (ALIM) Reports Q2 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.44 per share versus the Zacks Consensus Estimate of $0.06. This compares to loss of $0.45 per share a year ago.
zacks.com
Read More
Alimera Sciences Reports Second Quarter 2023 Results
ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the second quarter of 2023.
globenewswire.com
Read More
Alimera Sciences to Report Second Quarter 2023 Financial Results on August 10, 2023, and Provide Corporate Update
ATLANTA, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report second quarter financial results on August 10, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
globenewswire.com
Read More
Alimera Sciences (ALIM) Is Attractively Priced Despite Fast-paced Momentum
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Alimera Sciences (ALIM) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com
Read More
Are Medical Stocks Lagging Alimera Sciences (ALIM) This Year?
Here is how Alimera Sciences (ALIM) and Haemonetics (HAE) have performed compared to their sector so far this year.
zacks.com
Read More
Alimera (ALIM) Completes Enrollment in Eye Disease Study
Alimera (ALIM) announces completion of patient enrollment in its NEW DAY study to evaluate Iluvien 0.19 mg as a baseline therapy in diabetic macular edema. The stock surges 8% on Wednesday.
zacks.com
Read More
Alimera Sciences (ALIM) Shows Fast-paced Momentum But Is Still a Bargain Stock
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com
Read More
Alimera (ALIM) Up on Deal With Eyepoint for U.S. Rights to Yutiq
Alimera Sciences ALIM announced acquiring additional U.S. commercialization rights for 0.18 mg dose strength of Yutiq from EyePoint Pharmaceuticals, Inc. Yutiq is indicated to treat chronic non-infectious uveitis affecting the posterior segment of the eye.
zacks.com
Read More
How to Develop a Penny Stocks Trading Mentality
Can these tips help you become a better penny stocks trader? The post How to Develop a Penny Stocks Trading Mentality appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
pennystocks.com
Read More
Why Is Alimera Sciences (ALIM) Stock Up 21% Today?
Alimera Sciences (NASDAQ: ALIM ) stock is taking off on Thursday after signing a major deal with EyePoint Pharmaceuticals (NASDAQ: EYPT ). That agreement has Alimera Sciences acquiring additional commercialization rights for YUTIQ from EyePoint Pharmaceuticals.
investorplace.com
Read More
Alimera Sciences (ALIM) Reports Q1 Loss, Tops Revenue Estimates
Alimera Sciences (ALIM) came out with a quarterly loss of $0.71 per share versus the Zacks Consensus Estimate of a loss of $0.58. This compares to loss of $0.85 per share a year ago.
zacks.com
Read More
Alimera Sciences to Report First Quarter 2023 Financial Results on May 15, 2023, and Provide Corporate Update
ATLANTA, May 08, 2023 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces today that it will report first quarter financial results on May 15, 2023, prior to the market open. Management will host a conference call at 9:00 AM ET on the same day, to review financial results and provide an update on corporate developments.
globenewswire.com
Read More
Alimera Sciences (ALIM) Reports Q4 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -92.86% and 11.21%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
zacks.com
Read More
Alimera Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on Friday, March 31, 2023, and Provide Corporate Update
Conference Call to be held Friday, March 31, at 9:00am Eastern Time Conference Call to be held Friday, March 31, at 9:00am Eastern Time
globenewswire.com
Read More
7 Stocks That Could Implode at Any Moment
Although it's not a topic that everyone loves to hear, the concept of stocks to sell is a necessary one. Fundamentally, with fears of a global recession rising, investors need to start preparing for the worst.
investorplace.com
Read More
Alimera Sciences, Inc. (ALIM) Q3 2022 Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q3 2022 Results Conference Call November 14, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Group Laura Sorel - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences Third Quarter 2022 Financial Results and Corporate Update Conference Call.
seekingalpha.com
Read More
Alimera Sciences (ALIM) Reports Q3 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -102.70% and 12.83%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
zacks.com
Read More
Is Alimera Sciences (ALIM) Stock Outpacing Its Medical Peers This Year?
Here is how Alimera Sciences (ALIM) and Deciphera Pharmaceuticals, Inc. (DCPH) have performed compared to their sector so far this year.
zacks.com
Read More
Why Fast-paced Mover Alimera Sciences (ALIM) Is a Great Choice for Value Investors
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com
Read More
Alimera Sciences (ALIM) Is a Great Choice for "Trend" Investors, Here's Why
Alimera Sciences (ALIM) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
zacks.com
Read More
Is Alimera Sciences (ALIM) Outperforming Other Medical Stocks This Year?
Here is how Alimera Sciences (ALIM) and Centene (CNC) have performed compared to their sector so far this year.
zacks.com
Read More
Alimera Sciences to Present at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference
ATLANTA, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announced today that Rick Eiswirth, Alimera's President and Chief Executive Officer, will deliver a corporate presentation at the HC Wainwright 2nd Annual Ophthalmology Conference being held virtually on Wednesday, August 17, 2022.
globenewswire.com
Read More
Here Is Why Bargain Hunters Would Love Fast-paced Mover Alimera Sciences (ALIM)
Alimera Sciences (ALIM) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
zacks.com
Read More
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q2 2022 Results - Earnings Call Transcript
Alimera Sciences, Inc. (NASDAQ:ALIM ) Q2 2022 Earnings Conference Call July 27, 2022 9:00 AM ET Company Participants Scott Gordon - CORE, Investor Relations Rick Eiswirth - President & Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alex Nowak - Craig-Hallum Capital Yi Chen - H.C. Wainwright Operator Ladies and gentlemen, thank you for standing by.
seekingalpha.com
Read More
Alimera Sciences to Report Second Quarter 2022 Financial Results on Wednesday, July 27, 2022, and Provide Corporate Update
Conference Call to be held Wednesday July 27, at 9:00am Eastern Time Conference Call to be held Wednesday July 27, at 9:00am Eastern Time
globenewswire.com
Read More
Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q1 2022 Results - Earnings Call Transcript
Alimera Sciences, Inc (NASDAQ:ALIM ) Q1 2022 Earnings Conference Call May 9, 2022 9:00 AM ET Company Participants Scott Gordon - CORE IR Richard Eiswirth - President and Chief Executive Officer Phil Jones - Chief Financial Officer Conference Call Participants Alexander Nowak - Craig-Hallum Capital Group James Molloy - Alliance Global Partners Operator Ladies and gentlemen, thank you for standing by. Good morning and welcome to the Alimera Sciences First Quarter 2022 Financial Results and Corporate Update Conference Call.
seekingalpha.com
Read More
Alimera Sciences to Report First Quarter 2022 Financial Results on Monday, May 9, 2022, and Provide Corporate Update
Conference Call to be held the same day at 9:00am Eastern Time Conference Call to be held the same day at 9:00am Eastern Time
globenewswire.com
Read More
New Strong Sell Stocks for April 26th
ANIK, ALIM, and ADAP have been added to the Zacks Rank #5 (Strong Sell) List on April 26, 2022
zacks.com
Read More
New Strong Sell Stocks for March 30th
ALIM, APPF, and CNNE have been added to the Zacks Rank #5 (Strong Sell) List on March 30, 2022.
zacks.com
Read More
New Strong Sell Stocks for March 28th
ALIM, ANIK, and APPF have been added to the Zacks Rank #5 (Strong Sell) List on March 28, 2022
zacks.com
Read More
New Strong Sell Stocks for March 1st
AGIO, ALIM, and BV have been added to the Zacks Rank #5 (Strong Sell) List on March 1, 2022
zacks.com
Read More
Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q4 2021 Results - Earnings Call Transcript
Alimera Sciences, Inc (ALIM) CEO Richard Eiswirth on Q4 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
Alimera Sciences to Present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference
ATLANTA, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announces that Rick Eiswirth, Alimera's President and Chief Executive Officer will present at the MicroCap Rodeo Winter Wonderland Best Ideas Virtual Investor Conference, which is being held virtually from February 8 – 11, 2022.
globenewswire.com
Read More
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, announces that Rick Eiswirth, Alimera's President and Chief Executive Officer, will participate in three investor conference events in November.
globenewswire.com
Read More
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate Update
Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time
globenewswire.com
Read More
Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for
Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
Read More
ALIM Stock: Why It Increased Today
The stock price of Alimera Sciences Inc (NASDAQ: ALIM) increased by over 6% today. This is why it happened.
pulse2.com
Read More
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden in Patients with Diabetic Macular Edema
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN
globenewswire.com
Read More
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer., announces today that Chief Executive Officer Rick Eiswirth will present at the 23rd Annual H.C. Wainwright Global Investment Conference which is being held virtually from September 13 – 15, 2021.
globenewswire.com
Read More
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based European subsidiary, received pricing and reimbursement approval for ILUVIEN® for diabetic macular edema (DME) in Belgium from the National Institute for Health and Disability Insurance (INAMI). Pricing and reimbursement approval was sought and secured by Alimera's distribution partner in France and the Benelux region, Horus Pharma S.A.S. (Horus). Horus is currently in the launch phase in Belgium.
globenewswire.com
Read More
New Strong Sell Stocks for August 19th
ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
zacks.com
Read More
Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript
Alimera Sciences' (ALIM) CEO Rick Eiswirth on Q2 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
zacks.com
Read More
Recap: Alimera Sciences Q2 Earnings
Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78, which missed the estimate of $1.06.
benzinga.com
Read More
Alimera Sciences Announces Second Quarter 2021 Financial Results
ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the second quarter of 2021. Alimera will host a conference call today at 9:00 a.m. EDT to discuss these results.
globenewswire.com
Read More
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Update
Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time
globenewswire.com
Read More
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, today announced that management has been invited to present at the Summer Solstice - Best Ideas from the Buy Side Conference, which is being held virtually on June 1 – June 4, 2021.
globenewswire.com
Read More
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the expansion of its leadership team with the appointment of David Dyer, M.D. as chief retina specialist, effective today. Dr. Dyer brings his extensive medical knowledge and business expertise to the company, while continuing to see patients out of his longstanding practice in Kansas City, Missouri.
globenewswire.com
Read More
Alimera Sciences Inc. (ALIM) CEO Rick Eiswirth on Q1 2021 Results - Earnings Call Transcript
Alimera Sciences Inc. (ALIM) CEO Rick Eiswirth on Q1 2021 Results - Earnings Call Transcript
seekingalpha.com
Read More
Alimera Sciences (ALIM) Reports Q1 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
zacks.com
Read More
Alimera Sciences Announces First Quarter 2021 Financial Results
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, today announced financial results for the first quarter of 2021. Alimera will host a conference call on April 29, 2021, at 9:00 a.m. ET to discuss these results.
globenewswire.com
Read More
Week In Review: Sinopharm Transfers $4.6 Billion In Assets Including Two COVID-19 Vaccines
Sinopharm, China's large state-owned pharma, will transfer six of its vaccine companies to Beijing Tiantan Biological Products, a Shanghai-listed biopharma that is 50% owned by Sinopharm. Shanghai's SciNeuro Pharma in-licensed Greater China rights to Lilly's alpha-synuclein targeted antibody therapies, an expected therapy for Parkinson's.
seekingalpha.com
Read More
Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that Rick Eiswirth, President and Chief Executive Officer, will give a corporate presentation at the Zooming with LD Micro virtual conference on Thursday, April 15, 2021 at 11:00 AM ET followed by a live Q&A session with registered investors and other conference attendees. In addition, Mr. Eiswirth will be available for virtual one-on-one meetings the same day.
globenewswire.com
Read More
Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Global Life Sciences Conference to be held on March 9-10, 2021.
globenewswire.com
Read More
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call Transcript
Alimera Sciences, Inc. (ALIM) CEO Rick Eiswirth on Q4 2020 Results - Earnings Call Transcript
seekingalpha.com
Read More
Alimera Sciences Reports Fourth Quarter and 2020 Results
Fourth Quarter Highlights:
globenewswire.com
Read More
Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications
ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that ILUVIEN is now available in Finland for diabetic macular edema (DME) and non-infectious uveitis affecting the posterior segment (NIPU), and will be marketed by Alimera and distributed by Nordic Prime.
globenewswire.com
Read More
Alimera Sciences to Report Fourth Quarter and Full Year 2020 Financial Results on Wednesday, February 24, 2021 and Provide Corporate Update
Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time Conference Call to be held Thursday, February 25, 2021 at 9:00am Eastern Time
globenewswire.com
Read More
Alimera Sciences to Present at the Microcap Rodeo Winter Wonderland Conference
ATLANTA, Feb. 15, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the Microcap Rodeo Winter Wonderland Conference, which will be held from February 16-19, 2021.
globenewswire.com
Read More
Alimera Sciences, Inc. Discusses Its 2021 Global Expansion Strategy with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - February 1, 2021) - The Stock Day Podcast welcomed Alimera Sciences, Inc. (NASDAQ: ALIM) ("the Company"), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals. President and CEO of the Company, Rick Eiswirth, joined Stock Day host Everett Jolly. Jolly began the interview by asking about the Company's background and current projects. "We are an ophthalmology company, so we're focused on finding ways to treat diseases...
newsfilecorp.com
Read More
Alimera Sciences Announces Preliminary Top-line Results for Fourth Quarter and Full-Year 2020
ATLANTA, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals for the treatment of retinal diseases, announces preliminary consolidated net revenue for the fourth quarter of 2020 in excess of $13.5 million and annual 2020 consolidated net revenue in excess of $50.5 million. Alimera anticipates that cash on December 31, 2020 will be $11.2 million compared to $11.3 million on September 30, 2020.
globenewswire.com
Read More
Alimera Sciences to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference
ATLANTA, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that President and CEO Rick Eiswirth will present at the H.C. Wainwright Bioconnect 2021 Virtual Conference taking place January 11-14, 2021.
globenewswire.com
Read More
Alimera Sciences Announces Launch of ILUVIEN® in the Netherlands
ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications ILUVIEN has been launched for both Diabetic Macular Edema and Non-Infectious Posterior Uveitis Indications
globenewswire.com
Read More